Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
Journal Information
Full Title: Risk Manag Healthc Policy
Abbreviation: Risk Manag Healthc Policy
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Health Policy & Services
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Disclosure The authors report no conflicts of interest in this work."
"This work was supported by the National Natural Science Foundation of China (No. 72074123)."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025